Draft 2020 Chinese pharmacopeia includes hundreds of new pharmaceuticals

As currently drafted,  the 2020 Chinese Pharmacopeia, the benchmark publication on the safety and efficacy of pharmaceuticals legally available in China, includes 319 new entries. The publication includes more than 5,500 traditional Chinese and Western medicines.

The official compendium of the standards of purity, description, test, dosage, precaution, storage, and the strength for each drug legally marketed in China is published by the Chinese Pharmacopoeia Commission. It is designed to align with the current  National Essential Drug List (NEDL) and National Reimbursement Drug List (NRDL). The draft includes 2,712 chemical drugs and 2,711 traditional Chinese medicines, along with 153 biological products, 361 general technical requirements, 281 test methods and 335 guiding principles.